These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 25753670)

  • 21. Stabilization of expanded (CTG)•(CAG) repeats by antisense oligonucleotides.
    Nakamori M; Gourdon G; Thornton CA
    Mol Ther; 2011 Dec; 19(12):2222-7. PubMed ID: 21971425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fuchs' Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic Dystrophy.
    Mootha VV; Hansen B; Rong Z; Mammen PP; Zhou Z; Xing C; Gong X
    Invest Ophthalmol Vis Sci; 2017 Sep; 58(11):4579-4585. PubMed ID: 28886202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoplasmic CUG RNA foci are insufficient to elicit key DM1 features.
    Dansithong W; Wolf CM; Sarkar P; Paul S; Chiang A; Holt I; Morris GE; Branco D; Sherwood MC; Comai L; Berul CI; Reddy S
    PLoS One; 2008; 3(12):e3968. PubMed ID: 19092997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts.
    Fardaei M; Larkin K; Brook JD; Hamshere MG
    Nucleic Acids Res; 2001 Jul; 29(13):2766-71. PubMed ID: 11433021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1.
    Ait Benichou S; Jauvin D; De Serres-Bérard T; Pierre M; Ling KK; Bennett CF; Rigo F; Gourdon G; Chahine M; Puymirat J
    Gene Ther; 2022 Dec; 29(12):698-709. PubMed ID: 35075265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Approaches for Dominant Muscle Diseases: Highlight on Myotonic Dystrophy.
    Klein AF; Dastidar S; Furling D; Chuah MK
    Curr Gene Ther; 2015; 15(4):329-37. PubMed ID: 26122101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1.
    Hino S; Kondo S; Sekiya H; Saito A; Kanemoto S; Murakami T; Chihara K; Aoki Y; Nakamori M; Takahashi MP; Imaizumi K
    Hum Mol Genet; 2007 Dec; 16(23):2834-43. PubMed ID: 17728322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DM1 CTG expansions affect insulin receptor isoforms expression in various tissues of transgenic mice.
    Guiraud-Dogan C; Huguet A; Gomes-Pereira M; Brisson E; Bassez G; Junien C; Gourdon G
    Biochim Biophys Acta; 2007 Dec; 1772(11-12):1183-91. PubMed ID: 17950578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1.
    López-Morató M; Brook JD; Wojciechowska M
    Front Neurol; 2018; 9():349. PubMed ID: 29867749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy.
    Mulders SA; van den Broek WJ; Wheeler TM; Croes HJ; van Kuik-Romeijn P; de Kimpe SJ; Furling D; Platenburg GJ; Gourdon G; Thornton CA; Wieringa B; Wansink DG
    Proc Natl Acad Sci U S A; 2009 Aug; 106(33):13915-20. PubMed ID: 19667189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac elav-type RNA-binding protein (ETR-3) binds to RNA CUG repeats expanded in myotonic dystrophy.
    Lu X; Timchenko NA; Timchenko LT
    Hum Mol Genet; 1999 Jan; 8(1):53-60. PubMed ID: 9887331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted splice sequencing reveals RNA toxicity and therapeutic response in myotonic dystrophy.
    Tanner MK; Tang Z; Thornton CA
    Nucleic Acids Res; 2021 Feb; 49(4):2240-2254. PubMed ID: 33503262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1.
    Lee JE; Bennett CF; Cooper TA
    Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4221-6. PubMed ID: 22371589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy.
    Wang GS; Kearney DL; De Biasi M; Taffet G; Cooper TA
    J Clin Invest; 2007 Oct; 117(10):2802-11. PubMed ID: 17823658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BNA
    Manning KS; Rao AN; Castro M; Cooper TA
    ACS Chem Biol; 2017 Oct; 12(10):2503-2509. PubMed ID: 28853853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myotonic dystrophy associated expanded CUG repeat muscleblind positive ribonuclear foci are not toxic to Drosophila.
    Houseley JM; Wang Z; Brock GJ; Soloway J; Artero R; Perez-Alonso M; O'Dell KM; Monckton DG
    Hum Mol Genet; 2005 Mar; 14(6):873-83. PubMed ID: 15703191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DDX6 regulates sequestered nuclear CUG-expanded DMPK-mRNA in dystrophia myotonica type 1.
    Pettersson OJ; Aagaard L; Andrejeva D; Thomsen R; Jensen TG; Damgaard CK
    Nucleic Acids Res; 2014 Jun; 42(11):7186-200. PubMed ID: 24792155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy.
    Gao Z; Cooper TA
    Hum Gene Ther; 2013 May; 24(5):499-507. PubMed ID: 23252746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developmental insights into the pathology of and therapeutic strategies for DM1: Back to the basics.
    Chau A; Kalsotra A
    Dev Dyn; 2015 Mar; 244(3):377-90. PubMed ID: 25504326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FISH Protocol for Myotonic Dystrophy Type 1 Cells.
    Klein AF; Arandel L; Marie J; Furling D
    Methods Mol Biol; 2020; 2056():203-215. PubMed ID: 31586350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.